Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Amrutanjan Health Care's net current asset value per share for the quarter that ended in Jun. 2026 was ₹0.00.
The historical rank and industry rank for Amrutanjan Health Care's Net Current Asset Value or its related term are showing as below:
BOM:590006'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.23 Med: 10.22 Max: 13.67
Current: 9.26
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Amrutanjan Health Care was 13.67. The lowest was 8.23. And the median was 10.22.
BOM:590006's Price-to-Net-Current-Asset-Value is ranked worse than 67.05% of 604
companies
in the Drug Manufacturers industry
Industry Median: 6.035
vs BOM:590006: 9.26
Amrutanjan Health Care (BOM:590006) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Amrutanjan Health Care Net Current Asset Value Related Terms
Amrutanjan Health Care Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Amrutanjan Health Care's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amrutanjan Health Care Net Current Asset Value Chart
BOM:590006 vs ZTS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amrutanjan Health Care's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amrutanjan Health Care Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amrutanjan Health Care's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Amrutanjan Health Care's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹0.00 mean?
Amrutanjan Health Care (BOM:590006) has a Net Current Asset Value of ₹0.00 as of Jun. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Amrutanjan Health Care and its competitors. According to the industry distribution chart, Amrutanjan Health Care ranks #405 out of 604 companies in the Drug Manufacturers industry, placing it in the top 67.1%.
Is Amrutanjan Health Care's Net Current Asset Value too high?
Amrutanjan Health Care's current Net Current Asset Value is ₹0.00. Based on the distribution chart, Amrutanjan Health Care ranks #405 out of 604 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amrutanjan Health Care has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amrutanjan Health Care's Net Current Asset Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Amrutanjan Health Care ranks #405 out of 604 companies for Net Current Asset Value. This places Amrutanjan Health Care in the lower half of its industry. The industry median Net Current Asset Value is 6.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 6.04, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Amrutanjan Health Care and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 6.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amrutanjan Health Care's current Net Current Asset Value is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amrutanjan Health Care stock overvalued right now?
Based on GuruFocus' analysis, Amrutanjan Health Care (BOM:590006) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹827.69, compared to a current price of ₹490.35 — trading 40.8% below its estimated fair value. The current Net Current Asset Value is ₹0.00. Amrutanjan Health Care's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Amrutanjan Health Care (BOM:590006), the current Net Current Asset Value is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amrutanjan Health Care (BOM:590006) Overvalued in 2026?
Based on GuruFocus' analysis, Amrutanjan Health Care stock appears to be undervalued.
The current stock price of ₹490.35 is trading 40.8% below its estimated GF Value™ of ₹827.69.
GuruFocus considers Amrutanjan Health Care to be Significantly Undervalued.
Key valuation signals for BOM:590006:
Net Current Asset Value: ₹0.00
GF Value™: ₹827.69 vs. price of ₹490.35 (40.8% below fair value)
No single metric tells the full story. See the BOM:590006 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amrutanjan Health Care Ltd manufactures Ayurvedic and allopathic products. The company operates through the following segments: OTC Products, Beverages, and Others. The majority of the revenue is generated from its OTC segment which is engaged in the manufacturing products of pain management, congestion management, and hygiene. Its beverage segment includes manufacturing fruit juices and oral rehydration drinks. Some of its products include Roll-on, Spray, Balm, Cough Syrup, Sanitary napkins, and inhalers. Geographically, it generates the majority of the revenue from India.
71GF Score
Get the complete analysis for BOM:590006
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:590006 has been successfully added to your 
